<DOC>
	<DOCNO>NCT01167738</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Metformin hydrochloride may stop growth tumor cell block enzymes need cell growth . It yet know combination chemotherapy effective without metformin hydrochloride treat patient metastatic pancreatic cancer . PURPOSE : This randomized phase II trial study give cisplatin , epirubicin hydrochloride , capecitabine , gemcitabine hydrochloride together metformin hydrochloride see well work compare cisplatin , epirubicin hydrochloride , capecitabine , gemcitabine hydrochloride alone treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Metformin Hydrochloride Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess therapeutic activity chemotherapy comprise cisplatin , epirubicin hydrochloride , capecitabine , gemcitabine hydrochloride versus without metformin hydrochloride term 6-month progression-free survival patient metastatic pancreatic cancer . Secondary - To assess overall survival patient treat regimen . - To assess response rate patient treat regimen . - To assess duration response patient treat regimen . - To assess toxicity patient treated regimen . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin , epirubicin hydrochloride , gemcitabine hydrochloride day 1 15 . Patients also receive capecitabine metformin hydrochloride day 1-28 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive cisplatin , epirubicin hydrochloride , gemcitabine hydrochloride , capecitabine arm I . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma Metastatic ( stage IV ) disease Measurable disease No symptomatic brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Not pregnant nursing Adequate bone marrow , liver kidney function No previous concurrent malignancy sit except surgically cure carcinoma insitu cervix , basal cell squamous cell carcinoma skin , neoplasm without evidence disease within past 5 year No multiple severe disease would compromise safety ( i.e. , cardiac failure , previous myocardial infarction within past 4 month , cardiac arrhythmia , history psychiatric disability ) No alcohol abuse PRIOR CONCURRENT THERAPY : No prior chemotherapy metformin No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>